RESUMEN
OBJECTIVE: Rheumatoid arthritis is an inflammatory joint disease in which synovial iron deposition has been described. Transferrin receptor 2 (Tfr2) represents a critical regulator of systemic iron levels. Loss of Tfr2 function in humans and mice results in iron overload. As iron contributes to inflammatory processes, we investigated whether Tfr2-deletion affects the pathogenesis of inflammatory arthritis in an iron-dependent manner. METHODS: Using a global and conditional genetic disruption of Tfr2, we assessed the relevance of Tfr2 in K/BxN serum-transfer arthritis (STA) and macrophage polarization. RESULTS: Male Tfr2-/- mice subjected to STA developed pronounced joint swelling, and bone erosion as compared to Tfr2+/+ littermate-controls (P < 0.01). Furthermore, an increase of neutrophils and macrophages/monocytes was observed in the inflammatory infiltrate within the paws of Tfr2-/- mice. To elucidate whether Tfr2 in myeloid cells has a direct role in the pathogenesis of arthritis or whether the effects were mediated via the systemic iron overload, we induced STA in Tfr2fl/fl-LysMCre + mice, which showed normal iron-loading. Cre + female mice displayed increased disease development compared to Cre-controls. As macrophages regulate iron availability and innate immunity, we hypothesized that Tfr2-deficiency would polarize macrophages toward a pro-inflammatory state (M1) that contributes to arthritis progression. In response to IFN-γ stimulation, Tfr2-/- macrophages showed increased expression of M1-like cytokines, IFN-γ-target genes, nitric-oxide production, and prolonged STAT1 activation compared to Tfr2+/+ macrophages (P < 0.01), while pre-treatment with ruxolitinib abolished Tfr2-driven M1-like polarization. CONCLUSION: Taken together, these findings suggest a protective role of Tfr2 in macrophages on the progression of arthritis via suppression of M1-like polarization.
Asunto(s)
Artritis , Sobrecarga de Hierro , Humanos , Ratones , Masculino , Femenino , Animales , Ratones Noqueados , Hierro/metabolismo , Sobrecarga de Hierro/patología , Macrófagos/metabolismo , Artritis/metabolismo , Receptores de Transferrina/genéticaRESUMEN
The use of standard procedures for the diagnosis of osteoporosis and assessment of fracture risk significantly decreased during the COVID-19 pandemic, while the incidence of fragility fractures was mostly unaltered. Both COVID-19 per se and its treatments are associated with a negative impact on bone health. Preclinical models show that mice infected with SARS-CoV2 even without symptoms display loss of trabecular bone mass two weeks post infection, due to increased numbers of osteoclasts. Osteoporosis medications do not aggravate the clinical course of COVID-19, while preclinical data suggests possible beneficial effects of some therapies. While vitamin D deficiency is clearly associated with a worse clinical course of COVID-19, evidence of improved patient outcome with vitamin D supplementation is lacking. Osteoporosis treatment should not be generally discontinued, and recommendations for substituting therapies are available. Osteoporosis therapies do not interfere with the efficacy or side-effect profiles of COVID-19 vaccines and should not be stopped or indefinitely delayed because of vaccination.
Asunto(s)
COVID-19 , Fracturas Óseas , Osteoporosis , Animales , Vacunas contra la COVID-19 , Fracturas Óseas/complicaciones , Humanos , Ratones , Osteoporosis/tratamiento farmacológico , Pandemias , ARN Viral/uso terapéutico , SARS-CoV-2 , Vitamina D/uso terapéuticoRESUMEN
Prostate cancer (PCa) is the most frequent malignancy in older men with a high propensity for bone metastases. Characteristically, PCa causes osteosclerotic lesions as a result of disrupted bone remodeling. Extracellular vesicles (EVs) participate in PCa progression by conditioning the pre-metastatic niche. However, how EVs mediate the cross-talk between PCa cells and osteoprogenitors in the bone microenvironment remains poorly understood. We found that EVs derived from murine PCa cell line RM1-BM increased metabolic activity, vitality, and cell proliferation of osteoblast precursors by >60%, while significantly impairing mineral deposition (-37%). The latter was further confirmed in two complementary in vivo models of ossification. Accordingly, gene and protein set enrichments of osteoprogenitors exposed to EVs displayed significant downregulation of osteogenic markers and upregulation of proinflammatory factors. Additionally, transcriptomic profiling of PCa-EVs revealed the abundance of three microRNAs, miR-26a-5p, miR-27a-3p, and miR-30e-5p involved in the suppression of BMP-2-induced osteogenesis in vivo, suggesting the critical role of these EV-derived miRNAs in PCa-mediated suppression of osteoblast activity. Taken together, our results indicate the importance of EV cargo in cancer-bone cross-talk in vitro and in vivo and suggest that exosomal miRNAs may contribute to the onset of osteosclerotic bone lesions in PCa.
Asunto(s)
Complejo Multienzimático de Ribonucleasas del Exosoma/genética , Osteoblastos/fisiología , Neoplasias de la Próstata/genética , Animales , Huesos/metabolismo , Huesos/fisiología , Comunicación Celular , Línea Celular Tumoral , Proliferación Celular , Complejo Multienzimático de Ribonucleasas del Exosoma/metabolismo , Exosomas/genética , Vesículas Extracelulares/metabolismo , Expresión Génica/genética , Perfilación de la Expresión Génica/métodos , Regulación Neoplásica de la Expresión Génica/genética , Masculino , Células Madre Mesenquimatosas , Ratones , Ratones Endogámicos C57BL , MicroARNs/genética , Osteogénesis , Transcriptoma/genética , Microambiente TumoralRESUMEN
Glucocorticoids (GCs) are in widespread use to treat inflammatory bone diseases, such as rheumatoid arthritis (RA). Their anti-inflammatory efficacy, however, is accompanied by deleterious effects on bone, leading to GC-induced osteoporosis (GIO). These effects include up-regulation of the receptor activator of NF-κB ligand/osteoprotegerin (RANKL/OPG) ratio to promote bone-resorbing osteoclasts and include inhibition of bone-forming osteoblasts. We previously identified suppression of osteoblast differentiation by the monomer glucocorticoid receptor (GR) via the inhibition of Il11 expression as a crucial mechanism for GIO. Here we show that the GR-modulating substance compound A (CpdA), which does not induce GR dimerization, still suppresses proinflammatory cytokines in fibroblast-like synovial cells from patients with RA and in osteoblasts. In contrast to the full GR agonist dexamethasone, it does not unfavorably alter the RANKL/OPG ratio and does not affect Il11 expression and subsequent STAT3 phosphorylation in these cells. Notably, while dexamethasone inhibits osteoblast differentiation, CpdA does not affect osteoblast differentiation in vitro and in vivo. We describe here for the first time that selective GR modulators can act against inflammation, while not impairing osteoblast differentiation.
Asunto(s)
Glucocorticoides/efectos adversos , Osteoblastos/efectos de los fármacos , Osteoporosis/inducido químicamente , Osteoprotegerina/metabolismo , Receptores de Glucocorticoides/fisiología , Animales , Antiinflamatorios no Esteroideos/farmacología , Aziridinas/farmacología , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Dexametasona/farmacología , Femenino , Humanos , Interleucina-11/biosíntesis , Interleucina-11/genética , Masculino , Osteoblastos/metabolismo , Osteoclastos/efectos de los fármacos , Extractos Vegetales/farmacología , Ligando RANK/metabolismoRESUMEN
BACKGROUND: Phytoestrogens, especially genistein, have been shown to have bone beneficial effects in vitro and in vivo. However, the effect of glycitein on bone cells is not known. The aim of this study was to investigate the effects of glycitein on osteoclast differentiation and apoptosis in vitro. METHODS: Bone marrow-derived osteoclasts were cultured with various concentrations (0.01-100 nM) of glycitein. Osteoclast generation was assessed by the number of multinucleated, tartrate-resistant acid phosphatase (TRAP)-positive cells, and apoptosis by the activity of caspase 3/7. Bone-marrow-derived osteoblasts were cultured in the presence of 10 nM glycitein. Subsequently, gene expression levels of receptor activator of NFκB ligand (RANKL), osteoprotegerin (OPG), and interleukin-6 (IL-6) were determined by real-time PCR. RESULTS: Osteoclast generation was inhibited by glycitein in a biphasic-dose-dependent manner and showed the greatest inhibitory effects at 10 nM (-70%, p < 0.01). Glycitein increased caspase 3/7 activity by 15% at a concentration of 10 nM (p < 0.001). Further, 10 nM glycitein significantly decreased the expression of IL-6 (-53%, p < 0.05) and RANKL (-64%, p < 0.05) in osteoblasts but did not change mRNA levels of OPG. CONCLUSIONS: Our data demonstrate that glycitein suppresses osteoclast generation and induces osteoclast apoptosis in vitro to a similar extent as genistein and therefore suggests that glycitein may also exert bone beneficial effects in vivo.
Asunto(s)
Apoptosis/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Isoflavonas/farmacología , Osteoclastos/efectos de los fármacos , Fitoestrógenos/farmacología , Animales , Apoptosis/genética , Diferenciación Celular/genética , Relación Dosis-Respuesta a Droga , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Técnicas In Vitro , Interleucina-6/genética , Ratones , Osteoprotegerina/genética , Ligando RANK/genética , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Osteoporosis is a classical age-related disease that affects women more often than men. The hypothesis that osteoporosis is a consequence of estrogen deficiency, has been proposed as early as 1941 by Albright and colleagues. The exact mechanisms of this steroid hormone deficiency in postmenopausal women as well as in the elderly men are continuously being unraveled. Collectively, estrogen deficiency has direct as well as indirect impacts on bone metabolism all of which promote osteoclastogenesis. This review aims at shedding light on the endocrine and osteoimmunological mechanisms that lead to involutional osteoporosis.